Skip to main content

Table 2 Patient characteristics

From: A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

  Patients (N = 100)
Characteristics No.  
Age, years   
  Median   69
  Range   51-92
ECOG performance status   
  0 91  
  1 9  
HLA typing   
  A24 66  
  A2 21  
  A3 supertype 11  
  A26 2  
Baseline PSA, ng/ml   
  Median   29.8
  Range   0.2-2481
PSADT, months   
  Median   2
  Range   0.3-36+
Lymphocyte, 1300/μL   
  Low 41  
  High 59  
CRP, 3 μg/mL   
  Low 53  
  High 47  
SAA, 8 μg/mL   
  Low 27  
  High 76  
IL6, 2.4 pg/mL   
  Low 84  
  High 16  
Gleason score   
  ≤7 34  
  ≥8 57  
  Unknown 9  
Site of metastasis   
  no 14  
  Bone only 33  
  Bone and nodal/organ 40  
  Nodal/organ 13  
Prior chemotherapy   
  (-) 60  
  (+) 40  
  1. Abbreviations: PPV, personalized peptide vaccination; ECOG, Eastern Cooperative Oncology Group; HLA, human leucocyte antigen; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein; SAA, serum amyloid A; IL6, interleukin 6.